Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.